B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

B of A Securities analyst Alec Stranahan has maintained a 'Buy' rating on Krystal Biotech (NASDAQ: KRYS) and increased the price target from $392 to $400. This adjustment reflects a positive outlook for the company's stock performance.